Mankind Pharma IPO, Day 3: All details you want to know
This prevalent healthcare company has fixed its IPO price rate at Rs. 1026 to Rs. 1080 per equity share.
New Delhi: As news and an opportunity for investors, April 27 is marked as the last day to subscribe for Mankind Pharma’s IPO. Its Initial public offering started from April 25, 2023 and will be open till today (April 27) for bidding. As per the subscription data of its second day of bidding, the QIB or Qualified Institutional Buyers figured at 1.86x. on the other hand, the NII or Non- Institutional Investors marked as 1.02x – {(NII 10L+) – 1.21x, (NII 2L-10L) – 0.64x}. And it was 0.25x for Retail. The figure totaled 0.87x.
What is Mankind Pharma Ltd.?
It is basically an Indian pharmaceutical company whose healthcare products range from antibiotics, cardiovascular, gastrointestinal, erectile dysfunction, and dermal medications. It is widespread in therapeutic areas delivering acute and chronic healthcare products.
What is the IPO price for Mankind Pharma Ltd.?
This prevalent healthcare company has fixed its IPO price rate at Rs. 1026 to Rs. 1080 per equity share.
To understand, the company’s fundraising at the lower price band would be Rs. 4,110.03 crore. While at the higher mark, it will be Rs. 4,326.35 crore.
How has the company been performing?
According to reports, Mankind Pharma Ltd. reported its profit after tax (PAT) at Rs 1,452.96 crore and its revenue at Rs 7,977.58 crore in fiscal year 2021-22. To compare the financial period which ended in December 2022, Mankind’s PAT was marked at Rs 1,015.98 crore and its revenue was at Rs 6,777.82 crore.
According to the financial services platform, Groww, the company (Mankind) is witnessing a surge in its revenue figures. In the year 2022, it made Rs. 7782 crore of revenue. While in 2021, it was Rs. 6,214 crore and Rs. 5,865 crore in the year 2020.
Should you invest in the company?
Looking at the above-mentioned statistics, Mankind Pharma Ltd has been performing well for the past few years. The company has created a renowned brand reputation among consumers. It holds a strong market image while gradually widening its research expenditure and targeting its consumer needs. Evidently, it is fairly emerging among the top players of the pharmaceutical sector.